{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T13:01:32Z","timestamp":1770728492308,"version":"3.49.0"},"reference-count":34,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Introduction: The emergence and spread of multidrug-resistant infections has resulted in significant clinical and economic burdens. To address these infections, novel therapy combinations are needed. Ceftolozane\/tazobactam is a treatment option that targets multidrug-resistant pathogens and may offer improved patient outcomes compared to traditional antibiotics that are now often ineffective. Objectives: Our objective was to collate findings from comparative efficacy studies to assess the efficacy of ceftolozane\/tazobactam for the indications of complex intra-abdominal infection, complex urinary tract infection, ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Methods: Two systematic literature reviews were conducted, including randomized controlled trials comparing ceftolozane\/tazobactam with other interventions for complex intra-abdominal infection, complex urinary tract infection, ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia indications. The outcomes of interest were mortality, clinical cure and microbiological eradication. Results: Ceftolozane\/tazobactam was determined to be non-inferior to comparators for all outcomes of interest. All-cause mortality for ceftolozane\/tazobactam displayed non-inferiority to meropenem, with the largest numerical differences in all-cause mortality displayed in susceptible patients, such as those with severe renal impairment. Similarly, the clinical cure and microbiological eradication for ceftolozane\/tazobactam demonstrated non-inferiority compared to meropenem or levofloxacin. Conclusions: These reviews support the role of ceftolozane\/tazobactam as an alternative option, particularly when MDR pathogens are suspected or documented. Their findings may contribute to the standardization of treatment guidelines, ultimately helping to reduce the clinical and economic burdens associated with these infections.<\/jats:p>","DOI":"10.3390\/antibiotics15020190","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:13:32Z","timestamp":1770653612000},"page":"190","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ceftolozane\/Tazobactam for Complex and Resistant Infections: Systematic Reviews of Comparative Efficacy Studies"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5834-4063","authenticated-orcid":false,"given":"Ignacio","family":"Martin-Loeches","sequence":"first","affiliation":[{"name":"Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St. James\u2019s Hospital, D08 NHY1 Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan K.","family":"Shields","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6036-9526","authenticated-orcid":false,"given":"Emre","family":"Y\u00fccel","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalini","family":"Bagga","sequence":"additional","affiliation":[{"name":"CHEORS LLC, Chalfont, PA 18914, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maesumeh","family":"Korei","sequence":"additional","affiliation":[{"name":"CHEORS LLC, Chalfont, PA 18914, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hariprasad","family":"Esam","sequence":"additional","affiliation":[{"name":"CHEORS LLC, Chalfont, PA 18914, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Sharma","sequence":"additional","affiliation":[{"name":"CHEORS LLC, Chalfont, PA 18914, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5310-2326","authenticated-orcid":false,"given":"Carolyn","family":"Cameron","sequence":"additional","affiliation":[{"name":"MSD, Sydney 2113, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"ref_1","unstructured":"WHO (2026, February 01). Antimicrobial Resistance. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance."},{"key":"ref_2","first-page":"1","article-title":"Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015\u20132017","volume":"41","author":"Abner","year":"2020","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.37201\/req\/096.2021","article-title":"Clinical management of cUTI, cIAI, and HABP\/VABP attributable to carbapenem-resistant Gram-negative infections in Spain","volume":"34","author":"Ferrer","year":"2021","journal-title":"Rev. Espa\u00f1ola Quimioter."},{"key":"ref_4","unstructured":"European Centre for Disease Prevention and Control (2026, January 09). Point Prevalence Survey of Healthcareassociated Infections and Antimicrobial Use in European Acute Care Hospitals, 2022\u20132023. Available online: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/PPS-HAI-AMR-acute-care-europe-2022-2023."},{"key":"ref_5","unstructured":"Centers for Disease Control and Prevention (U.S.), and National Center for Emerging and Zoonotic Infectious Diseases, Division of Healthcare Quality Promotion, Antibiotic Resistance Coordination and Strategy Unit (2019). Antibiotic Resistance Threats in the United States, 2019."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990\u20132021: A systematic analysis with forecasts to 2050","volume":"404","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"key":"ref_7","unstructured":"McDonnell, A., Countryman, A., Laurence, T., Gulliver, S., Drake, T., Edwards, S., Kenny, C., Lamberti, O., Morton, A., and Shafira, A. (2024). Forecasting the Fallout from AMR: Economic Impacts of Antimicrobial Resistance in Humans, Center for Global Development."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.37201\/req\/s01.10.2021","article-title":"Ceftolozane-tazobactam: When, how and why using it?","volume":"34","author":"Montero","year":"2021","journal-title":"Rev. Espa\u00f1ola Quimioter."},{"key":"ref_9","first-page":"825","article-title":"Ceftolozane\/Tazobactam: A new option in the treatment of complicated gram-negative infections","volume":"39","author":"Sorbera","year":"2014","journal-title":"Pharm. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): A randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/jac\/dkab494","article-title":"Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane\/tazobactam and meropenem for treatment of hospital-acquired\/ventilator-associated bacterial pneumonia","volume":"77","author":"Timsit","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s13054-021-03694-3","article-title":"Ceftolozane\/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: Subset analysis of the ASPECT-NP randomized, controlled phase 3 trial","volume":"25","author":"Timsit","year":"2021","journal-title":"Crit. Care"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13613-022-01084-8","article-title":"Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane\/tazobactam versus meropenem: A subset analysis of the phase 3, randomized, controlled ASPECT-NP trial","volume":"13","author":"Shorr","year":"2023","journal-title":"Ann. Intensive Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s13054-021-03773-5","article-title":"Ceftolozane\/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial","volume":"25","author":"Shorr","year":"2021","journal-title":"Crit. Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e00731-20","DOI":"10.1128\/AAC.00731-20","article-title":"Outcomes in participants with renal impairment from a phase 3 clinical trial for ceftolozane\/tazobactam treatment of nosocomial pneumonia (ASPECT-NP)","volume":"64","author":"Huntington","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s13054-022-04192-w","article-title":"Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired\/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane\/tazobactam versus meropenem","volume":"26","author":"Kollef","year":"2022","journal-title":"Crit. Care"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1093\/jac\/dkac184","article-title":"Ceftolozane\/tazobactam for hospital-acquired\/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: A subgroup analysis of the ASPECT-NP clinical trial","volume":"77","author":"Paterson","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_18","unstructured":"Martin-Loeches, I., Kivistik, U., Nov\u00e1cek, M., R\u00e9a-Neto, A., Timsit Fran\u00e7ois, J., Shime, N., Wunderink, R.G., and Kollef, M.H. (2019). Clinical and Microbiologic Outcomes by Causative Pathogen in the ASPECTNP Randomised, Controlled, Phase III Trial Evaluating Ceftolozane\/Tazobactam for Treatment of Ventilator-Associated Pneumonia, ESCMID."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: Results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1128\/AAC.03074-15","article-title":"Characteristics and outcomes of complicated intra-abdominal infections involving Pseudomonas aeruginosa from a randomized, double-blind, phase 3 ceftolozane-tazobactam study","volume":"60","author":"Miller","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijid.2022.08.003","article-title":"A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane\/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections","volume":"123","author":"Sun","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: A randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1093\/jac\/dkw053","article-title":"Efficacy of ceftolozane\/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacinresistant pathogens: Results from the ASPECT-cUTI trial","volume":"71","author":"Huntington","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1038\/s41598-020-59794-7","article-title":"Infection in advanced chronic kidney disease and subsequent adverse outcomes after dialysis initiation: A nationwide cohort study","volume":"10","author":"Chang","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Soriano, A., Puzniak, L., Paterson, D., Thalhalmmer, F., Kluge, S., Viale, P., and Kaul, S. (2019). 2279. Study of Prescribing patterns and Effectiveness of Ceftolozane\u2013tazobactam (C\/T): Real-world Analysis (SPECTRA): A multi-national, multicenter observational study. Open Forum Infectious Diseases, Oxford University Press.","DOI":"10.1093\/ofid\/ofz360.1957"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1093\/jac\/dkae313","article-title":"Comparative evaluation of early treatment with ceftolozane\/tazobactam versus ceftazidime\/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa","volume":"79","author":"Lodise","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S1473-3099(24)00648-0","article-title":"Effectiveness of ceftazidime\u2013avibactam versus ceftolozane\u2013tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): A multicentre, retrospective, observational study","volume":"25","author":"Shields","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e02318-20","DOI":"10.1128\/AAC.02318-20","article-title":"New perspectives on antimicrobial agents: Ceftolozane-tazobactam","volume":"65","author":"Lizza","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e01587-18","DOI":"10.1128\/AAC.01587-18","article-title":"Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program","volume":"62","author":"Sader","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1128\/CMR.00117-14","article-title":"The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria","volume":"28","author":"Li","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Tebano, G., Zaghi, I., Cricca, M., and Cristini, F. (2024). Antibiotic Treatment of Infections Caused by AmpC-Producing Enterobacterales. Pharmacy, 12.","DOI":"10.3390\/pharmacy12050142"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1128\/CMR.18.4.638-656.2005","article-title":"Antimicrobial stewardship programs in health care systems","volume":"18","author":"MacDougall","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/2\/190\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:33:16Z","timestamp":1770654796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/2\/190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["antibiotics15020190"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15020190","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]}}}